RecruitingNot Applicable

Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients

United States100 participantsStarted 2024-07-03

Plain-language summary

The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult patients over 18 years of age
✓. Lung transplant candidates with positive CMV IgG
✓. Anticipated to receive a lung transplant (both double lung and single lung)

Exclusion criteria

✕. Negative CMV IgG prior transplant
✕. Pregnant or breastfeeding women
✕. HIV infected patients
✕. Combined organ (e.g., lung-heart, lung-kidney) transplant candidates

What they're measuring

Positive CMV Immunoglobulin (IgG) positive lung transplant

Timeframe: Up to 1 year

Trial details

NCT IDNCT06494033

SponsorUniversity of Miami

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-30

Contact for this trial

Yoichiro Natori, MD

3053556323 yxn138@med.miami.edu

View on ClinicalTrials.gov More Lung Diseases trials